stockrowKymera Therapeutics, Inc.
KYMR Healthcare Biotechnology
Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024.
- Revenue
- +466.4%
- EPS
- −40.3%
- Free cash flow
- −186.6%
- Total debt
- −66.6%
Quarter to September 2026, against a year earlier
Follow KYMR
Alert me
Kymera Therapeutics, Inc. (KYMR) EV/Sales
As of 5 November 2026, Kymera Therapeutics, Inc. (KYMR) trades at a EV/Sales of 111×. Over the past ten years it has ranged from 0.0× (September 2020) to 208× (June 2026); the current reading is higher than 89% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 146× | 171.50% |
| FY2024 | 53.8× | 282.32% |
| FY2023 | 14.1× | (29.43%) |
| FY2022 | 19.9× | (44.26%) |
| FY2021 | 35.8× | 56.08% |
| FY2020 | 22.9× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 101× | (30.68%) |
| Mar 2026 | 145× | (0.60%) |
| Dec 2025 | 146× | 43.96% |
| Sep 2025 | 101× | 59.31% |
| 23 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PCVX Vaxcyte, Inc. compare | n/m |
| BMRN BioMarin Pharmaceutical Inc. compare | 3.9× |
| CAI Caris Life Sciences,�Inc. compare | 6.8× |
| TECH Bio-Techne Corp compare | 9.3× |
| TGTX TG Therapeutics, Inc. compare | 10.5× |
| TWST Twist Bioscience Corporation compare | 17.3× |
| IBRX ImmunityBio, Inc. compare | 56.5× |
| KYMR Kymera Therapeutics, Inc. | 111× |
| SMMT Summit Therapeutics PLC compare | 15,046× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on KYMR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement